Feb 24, 2021
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Months
Feb 08, 2021
Janssen Announces Treatment with ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
Jan 28, 2021
New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
Jan 28, 2021
Fifth Anniversary Blue Jacket Fashion Show Featuring Billy Porter, André Leon Talley, Mario Cantone, Mike Woods, Dominic Fumusa and More Goes Virtual to Raise Awareness and Funds for Prostate Cancer Research
Jan 21, 2021
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
Jan 15, 2021
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
Jan 15, 2021
Multimedia Now Available: Learn More About Light Chain (AL) Amyloidosis and a New Treatment Option
Dec 21, 2020
Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Dec 05, 2020
Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
Dec 04, 2020
Data from the APOLLO Study Show Clinically Meaningful Response with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Regimen After First or Subsequent Relapse in Multiple Myeloma
Nov 13, 2020
Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa
Nov 06, 2020
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials
Nov 05, 2020
Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
Nov 02, 2020
Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supplemental New Drug Application to U.S. FDA for Treatment of Schizophrenia in Adults
Oct 26, 2020
Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO® (rivaroxaban) in Patients with Peripheral Artery Disease
Oct 19, 2020
Janssen Demonstrates Strong Commitment To Research And Development Of Therapies For Inflammatory Bowel Diseases With Nine Data Presentations At ACG 2020
Sep 30, 2020
SIMPONI ARIA® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
Sep 11, 2020
Janssen Highlights Impact of Multiple Sclerosis-Related Fatigue with Real-World Study Data Presentation at MSVirtual2020 and Global Patient Survey
Aug 20, 2020
U.S. FDA Approves New DARZALEX® (daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
Jul 22, 2020
(n)SPRAVATO® (esketamine)* Nasal Spray is Available for Canadian Patients